Arrowhead Pharmac…
USUSDArrowhead Pharmaceuticals Inc (US:ARWR) — Biotechnology: Pharmaceutical Preparations. Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- arrowheadpharma.com
- Сектор
- Health Care · Biotechnology: Pharmaceutical Preparations
- Штаб-квартира
- Pasadena, United States
- Генеральный директор
- Christopher R. Anzalone
- Сотрудники
- 711
- Основана
- 2004
- Акций в обращении
- 141.25 млн на 2026-07-30
- Свободное обращение
- 122.45 млн
- Рыночная капитализация
- 9.22 млрд USD
- Инсайдеры
- 3.66%
- Институциональные инвесторы
- 85.47%
- Отрасль (SIC)
- Pharmaceutical Preparations
- ISIN
- US04280A1007
- LEI
- 549300O3CSB8T7OZ3D66
- FCF
- −75.1 млн USD
- Долг
- 181 млн USD
- Прибыль и FCF — за 12 месяцев до 30.06.2026 года (последний отчет компании).
Описание
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Новости этой недели
Новостей с сайта компании пока нет.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| Blackrock Inc. | 10.53% | 14.83 млн | 2026-06-30 |
| Avoro Capital Advisors L… | 8.06% | 11.36 млн | 2026-06-30 |
| FMR, LLC | 5.71% | 8.04 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.51% | 6.35 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 6.11 млн | 2026-06-30 |
| State Street Corporation | 4.04% | 5.69 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 3.5% | 4.93 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.01% | 4.25 млн | 2026-06-30 |
| NORGES BANK | 2.77% | 3.9 млн | 2026-06-30 |
| Invesco Ltd. | 2.76% | 3.88 млн | 2026-06-30 |
| ANZALONE CHRISTOPHER RIC… | ≈2.69% | 3.79 млн | 2026-01-02 |
| Geode Capital Management… | 2.51% | 3.53 млн | 2026-06-30 |
| Fred Alger Management, L… | 2.34% | 3.3 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 3.07 млн | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.81% | 2.55 млн | 2026-07-31 |
| Invesco Exchange-Traded… | 1.27% | 1.79 млн | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.26% | 1.77 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 1.61 млн | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.05% | 1.48 млн | 2026-08-31 |
| SPDR S&P MIDCAP 400 ETF… | 0.73% | 1.03 млн | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.69% | 968 738 | 2026-07-31 |
| O'BRIEN PATRICK C (Chief… | ≈0.39% | 547 408 | 2026-01-06 |
| MYSZKOWSKI KENNETH ALLEN… | ≈0.32% | 455 433 | 2025-01-07 |
| HAMILTON JAMES C (Office… | ≈0.16% | 226 958 | 2026-04-23 |
| APEL DANIEL JOSEPH (Chie… | ≈0.12% | 162 905 | 2026-04-22 |
| GIVEN DOUGLAS BRUCE (Dir… | ≈0.09% | 124 167 | 2024-12-17 |
| PERRY MICHAEL S (Directo… | ≈0.08% | 111 459 | 2026-08-18 |
| FERRARI MAURO (Director) | ≈0.05% | 69 053 | 2025-12-26 |
| WADDILL WILLIAM D (Direc… | ≈0.04% | 56 563 | 2025-12-19 |
| LU HONGBO B (Director) | ≈0.04% | 52 012 | 2026-05-12 |
